Dimerix is a clinical-stage biopharmaceutical company, with a portfolio of drug candidates for inflammatory diseases, including kidney and respiratory diseases.

Dimerix' lead candidate is in Phase 3 clinical trials for a rare type of kidney disease. Dimerix encourages collaboration and is well positioned to discuss partnering and product development.

2023 Rights Issue Prospectus and Target Market Determinations
Technology

Technology

Dimerix uses innovative Receptor-HIT technology to study receptor heteromers and uncover pharmaceutical products that will improve patients' lives.

Find out more
Product Pipeline

Product Pipeline

Dimerix develops new therapies through the clinic to commercialization. Our lead product is DMX-200 for FSGS kidney disease, currently in a Phase 3 clinical trial.

Find out more